Study identifier:D6997C00057
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A double-blind, randomized, multicentre trial to compare the anti-tumour effects and tolerability of a 500 mg dose of Faslodex (fulvestrant) plus Arimidex (anastrozole) with a 500 mg dose of Faslodex(fulvestrant) alone and with Arimidex(anastrozole) alone, in postmenopausal women prior to surgery for primary breast cancer
Breast Cancer
Phase 2
No
Fulvestrant, Anastrazole
Female
120
Interventional
N/A
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Jul 2012 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Active Comparator: 1 Anastrozole Monotherapy | Drug: Anastrazole oral tablet Other Name: Arimidex Other Name: ZD1033 |
Experimental: 2 Fulvestrant Monotherapy | Drug: Fulvestrant 500 mg intramuscular injection Other Name: Faslodex Other Name: ZD9238 |
Experimental: 3 Anastrozole + Fulvestrant | Drug: Fulvestrant 500 mg intramuscular injection Other Name: Faslodex Other Name: ZD9238 Drug: Anastrazole oral tablet Other Name: Arimidex Other Name: ZD1033 |